- Details
- Tom Keane welcomes Evan Yu to discuss the newest therapeutic options for patients with metastatic hormone-sensitive prostate cancer. Dr. Yu details the most crucial studies to date demonstrating improved OS in mHSPC patients, including the ARCHES , ENZAMET , STAMPEDE , and TITAN clinical trials. Additionally, he touches on the survival benefit shown in the CHAARTED trial. Dr. Yu provides a compreh...
|
- Details
- Hannah Rush joins Alicia Morgans discussing the quality of life outcomes we have seen from patients receiving docetaxel or abiraterone in the STAMPEDE trial. STAMPEDE is a multi-arm, multi-stage trial investigating various therapeutic strategies for the management of locally advanced or metastatic hormone-naïve prostate cancer. In recent years, both docetaxel and abiraterone have been shown to imp...
|
- Details
- Christopher Sweeney joins Charles Ryan to discuss the topic of hormone-sensitive prostate cancer, specifically concentrating on how clinicians can confront and categorize their patients with the disease. In continuing the ongoing conversation of the optimal approach for a high-volume patient, Dr. Sweeney uses evidence from current clinical trials to outline optional alternatives to abiraterone tre...
|
- Details
- Nick James, a Professor of Clinical Oncology at the Institute of Cancer Research joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses the developments around the high-volume/low-volume disease in metastatic hormone-sensitive disease from the STAMPEDE trial. They also discuss relapsed disease versus de novo metastatic disease. Biographies: P...
|
- Details
- Kenneth Pienta joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019) to discuss the biology of prostate cancer, and to share a clinician's perspective of thinking about the biology of this disease. This is a look at the current year and some of the significant findings that have changed the way we look at treating prostate cancer. The STAMPEDE data sho...
|
- Details
- In this conversation with Alicia Morgans, Matthew Smith shares highlights from his 2019 European Society for Medical Oncology annual meeting, (ESMO) presentation. He presented the updated survival results from SPARTAN, A study of apalutamide (ARN-509) in men with non-metastatic castration-resistant prostate cancer (nmCRPC), a pivotal study which led to the approval of apalutamide for men with nmCR...
|
- Details
- In this conversation, Neeraj Agarwal joins Petros Grivas to discuss the Patient-Reported Outcomes (PRO) data from the TITAN study, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. This data was presented at ESMO 2019. The Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic hormone-sensitive prostate cancer. (mHSPC) in Sept...
|
- Details
- Using various volume and risk criteria used worldwide for the treatment related to docetaxel and abiraterone in metastatic hormone-sensitive prostate cancer, Noel Clarke and colleagues have gathered and correlated large volumes of imaging data on treatment and outcomes from within the UK within the STAMPEDE trial. In his discussion with Charles Ryan, Noel Clarke shares details of the sub-analysis...
|
- Details
- Mary-Ellen Taplin presents on the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel or AR pathway inhibitors in the metastatic hormone-sensitive prostate cancer (mHSPC) setting. There are currently no prospective clinical trial data to guide the optimal selection of treatment for first-line mCRPC after ADT/docetaxel or ADT/AR-inhibition. Dr. Taplin exp...
|
- Details
- The aim of this presentation by Gerhardt (Gert) Attard at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 was to provide the research community with the information required to make the right choice on the dose and regimen of prednisone to combine with abiraterone and indications for combining dexamethasone with abiraterone, how to maximize therapy of steroids with abiraterone aceta...
|
